Table 2.
Patient condition post CD137L-DC-EBV-Vax treatment
| Study ID | Measurable disease | Evaluable disease on consenting | Pre-treatment albumin | Pre-treatment cortico-steroid | Cells admini-stered × 106 | Best res-ponse | PFS (weeks) from start of treatment | OS (weeks) from start of treatment |
|---|---|---|---|---|---|---|---|---|
| EBV001 | No | Yes | 50 | No | 16.7 | PD | 3 | 10 |
| EBV002 | Yes | Yes | 40 | No | 5.44 | PD | 4 | 75 |
| EBV003 | No | Yes | 46 | Yes – EMLA | 31.13 | SD | 102* | 102* |
| EBV004 | Yes | Yes | 46 | No | 17.23 | PD | 17 | 161* |
| EBV006 | No | No | 41 | No | 50.0 | SD | 136* | 136* |
| EBV007 | Yes | Yes | 38 | Yes – EMLA | 19.19 | PD | 15 | 100 |
| EBV008 | No | Yes | 46 | Yes – EMLA | 12.05 | SD | 107* | 107* |
| EBV009 | Yes | Yes | 48 | No | 22.68 | SD | 112* | 112* |
| EBV010 | Yes | 48 | No | 13.72 | PD | 4 | 64 | |
| EBV011 | Yes | Yes | 43 | Yes – EMLA | 27.89 | PR | 32 | 32 |
| EBV013 | Yes | Yes | 46 | Yes – EMLA | 41.63 | PD | 16 | 81 |
| EBV014 | Yes | Yes | 38 | No | 29.09 | PD | 16 | 71 |
PFS: Progression free survival
EMLA: Lidocaine/prilocaine cream
*: censored